ARCA biopharma Company Profile (NASDAQ:ABIO)

About ARCA biopharma

ARCA biopharma logo

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: ABIO
CUSIP:

Key Metrics:

Previous Close: $2.91
50 Day Moving Average: $2.94
200 Day Moving Average: $3.25
52-Week Range: $2.73 - $6.97
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -2.39
P/E Growth: 0.00
Market Cap: $25.75M
Outstanding Shares: 9,066,000
Beta: 1.45

Profitability:

Return on Equity: -37.40%
Return on Assets: -35.70%

Debt:

Current Ratio: 15.82%
Quick Ratio: 15.82%

Additional Links:

Companies Related to ARCA biopharma:

Consensus Ratings for ARCA biopharma (NASDAQ:ABIO) (?)

Ratings Breakdown:	2 Hold Ratings
Consensus Rating:	Hold (Score: 2.00)
Consensus Price Target:	$4.00 (40.35% upside)

Analysts' Ratings History for ARCA biopharma (NASDAQ:ABIO)

Show:

Date	Firm	Action	Rating	Price Target	Details
2/23/2016	Royal Bank Of Canada	Reiterated Rating	Sector Perform	$5.00 -> $4.00
2/23/2016	Cowen and Company	Reiterated Rating	Market Perform	$5.50 -> $4.00

(Data available from 9/30/2014 forward)

Earnings History for ARCA biopharma (NASDAQ:ABIO)

Date	Quarter	Consensus Estimate	Actual EPS	Release Link	Conference Call
11/10/2016
8/9/2016	Q216		($0.43)	View	N/A
11/21/2014		($0.15)	($0.11)	View	N/A
8/19/2014		($0.13)	($0.11)	View	N/A
5/29/2014		($0.12)	($0.13)	View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for ARCA biopharma (NASDAQ:ABIO)

Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.19 EPS

Dividend History for ARCA biopharma (NASDAQ:ABIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ARCA biopharma (NASDAQ:ABIO)

Insider Ownership Percentage: 2.46%
Institutional Ownership Percentage: 66.45%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/20/2016	Christopher David Ozeroff	VP	Sell	1,185	$2.89	$3,424.65
9/20/2016	Michael R. Bristow	Insider	Sell	1,972	$2.89	$5,699.08
9/20/2016	Thomas A. Keuer	COO	Sell	714	$2.89	$2,063.46
9/19/2016	Brian L. Selby	VP	Sell	476	$2.91	$1,385.16
4/5/2016	Christopher David Ozeroff	VP	Sell	366	$3.52	$1,288.32
4/5/2016	Michael R Bristow	Insider	Sell	724	$3.52	$2,548.48
4/5/2016	Thomas A Keuer	COO	Sell	384	$3.52	$1,351.68
4/4/2016	Brian L Selby	VP	Sell	1,114	$3.52	$3,921.28
3/1/2016	Christopher David Ozeroff	VP	Sell	458	$3.51	$1,607.58
3/1/2016	Michael R. Bristow	Insider	Sell	752	$3.50	$2,632.00
3/1/2016	Thomas A. Keuer	COO	Sell	457	$3.53	$1,613.21
9/18/2015	Christopher David Ozeroff	VP	Sell	1,129	$6.32	$7,135.28
3/2/2015	Brian L Selby	VP	Sell	1,125	$0.71	$798.75
3/2/2015	Michael R Bristow	Insider	Sell	5,446	$0.71	$3,866.66
1/16/2015	Riley Mccormack	Major Shareholder	Sell	350,000	$0.76	$266,000.00
1/7/2015	Riley Mccormack	Major Shareholder	Sell	550,000	$0.92	$506,000.00
9/18/2014	Michael R Bristow	CEO	Sell	13,853	$1.30	$18,008.90
9/18/2014	Patrick M Wheeler	CFO	Sell	8,246	$1.31	$10,802.26
2/4/2014	Riley Mccormack	Major Shareholder	Buy	1,000,000	$1.70	$1,700,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for ARCA biopharma (NASDAQ:ABIO)

Date	Headline
	ARCA Biopharma : Assigned Patent (NASDAQ:ABIO) www.4-traders.com - September 22 at 3:15 PM
	ARCA biopharma Named Winner of Corporate LiveWire Healthcare and Lifesciences Innovation Award (NASDAQ:ABIO) finance.yahoo.com - September 13 at 3:15 PM
	EARS Faces The Music, ABIO On Track, TEVA Gets EU Nod For Asthma Drug (NASDAQ:ABIO) www.rttnews.com - August 19 at 11:29 AM
	ARCA BIOPHARMA, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (NASDAQ:ABIO) www.4-traders.com - August 18 at 8:39 PM
	BRIEF-Arca says 100th patient randomized into the genetic-AF phase 2b/3 clinical trial (NASDAQ:ABIO) www.reuters.com - August 18 at 3:15 PM
	ARCA biopharma Announces 100th Patient Randomized into the Genetic-AF Phase 2B/3 Clinical Trial (NASDAQ:ABIO) www.publicnow.com - August 18 at 11:39 AM
	ARCA biopharma : Announces Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ABIO) www.4-traders.com - August 9 at 8:50 PM
	ARCA biopharma Announces Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ABIO) www.publicnow.com - August 9 at 8:50 PM
	Albioma :ABIO-FR: Earnings Analysis: For the six months ended June 30, 2016 : August 3, 2016 (NASDAQ:ABIO) www.capitalcube.com - August 3 at 11:48 AM
	Form 4 ARCA biopharma, Inc. For: Jun 09 Filed by: Selby Brian L. (NASDAQ:ABIO) www.streetinsider.com - June 15 at 3:16 PM
	ARCA BIOPHARMA, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K) (NASDAQ:ABIO) www.4-traders.com - June 15 at 3:16 PM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o (NASDAQ:ABIO) biz.yahoo.com - June 13 at 5:01 PM
	ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update - Business Wire (press release) (NASDAQ:ABIO) www.businesswire.com - May 12 at 9:47 AM
	ARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update (NASDAQ:ABIO) www.publicnow.com - May 11 at 7:07 PM
	ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:ABIO) biz.yahoo.com - May 11 at 4:49 PM
	ARCA Biopharma, Inc. (ABIO) Broker Price Targets For The Coming Week - Share Trading News (NASDAQ:ABIO) www.sharetrading.news - May 8 at 8:44 AM
	Broker Roundup For ARCA Biopharma, Inc. (ABIO) - Share Trading News (NASDAQ:ABIO) www.sharetrading.news - May 5 at 9:16 AM
	Latest Analyst Ratings For ARCA Biopharma, Inc. (ABIO) - Share Trading News (NASDAQ:ABIO) www.sharetrading.news - April 28 at 9:30 AM
	Arca Biopharma Inc (NASDAQ:ABIO)'s Company Shares Increased 0.28% After Low Volatility - CCH Daily News (NASDAQ:ABIO) cchdailynews.com - April 27 at 10:51 AM
	Next Weeks Broker Price Targets For ARCA Biopharma, Inc. (ABIO) - Share Trading News (NASDAQ:ABIO) www.sharetrading.news - April 27 at 10:51 AM
	Investors Watch List: ARCA biopharma, Inc. (NASDAQ:ABIO), Idera Pharmaceuticals (NASDAQ:IDRA), EverBank ... - KC Register (NASDAQ:ABIO) www.kcregister.com - April 26 at 10:20 AM
	What's in Arca Biopharma Inc After Forming Multiple Bottom? - The Post (NASDAQ:ABIO) www.bibeypost.com - April 26 at 10:20 AM
	Pipeline of congestive heart failure (heart failure) market H1 2016published by leading research firm (NASDAQ:ABIO) www.whatech.com - April 26 at 10:20 AM
	Arca Biopharma Incorporated (NASDAQ:ABIO) Short Interest Decreased By 10.89% (NASDAQ:ABIO) www.bibeypost.com - April 26 at 10:20 AM
	ARCA Biopharma, Inc. (ABIO) Latest Broker Views - Risers & Fallers (NASDAQ:ABIO) www.risersandfallers.com - April 21 at 10:25 AM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:ABIO) biz.yahoo.com - April 18 at 4:31 PM
	ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial - Business Wire (press release) (NASDAQ:ABIO) www.businesswire.com - April 18 at 10:27 AM
	ARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial (NASDAQ:ABIO) finance.yahoo.com - April 18 at 9:00 AM
	Arca Biopharma Incorporated (NASDAQ:ABIO) Shorted Shares Decreased By 10.89% - Stock Caller (NASDAQ:ABIO) www.stockcaller.com - April 15 at 1:22 PM
	Analyst Coverage: ARCA Biopharma, Inc. (ABIO) - Risers & Fallers (NASDAQ:ABIO) www.risersandfallers.com - April 12 at 1:18 PM
	Ra Capital Management Lowers stake in Arca Biopharma Inc (ABIO) - The Sussex Pilot (NASDAQ:ABIO) sussexpilot.com - April 8 at 1:29 PM
	Watch for Action: BGC Partners (NASDAQ:BGCP), ARCA biopharma (NASDAQ:ABIO), Vale S.A. (NYSE:VALE ... - Property Mentor (NASDAQ:ABIO) www.propertymentorgroup.com - April 7 at 1:48 PM
	Arca Biopharma, Inc. (ABIO) Files Form 4 Insider Selling : Thomas A Keuer Sells 384 Shares - SCSUCollegian (NASDAQ:ABIO) www.thescsucollegian.com - April 7 at 1:48 PM
	Broker Changes For ARCA Biopharma, Inc. (ABIO) - Risers & Fallers (NASDAQ:ABIO) www.risersandfallers.com - April 5 at 2:52 PM
	After Last Week What Do Analysts Think Of ARCA Biopharma, Inc. (ABIO) - Share Trading News (NASDAQ:ABIO) www.sharetrading.news - April 3 at 2:35 PM
	Array Bio ends late-stage study of ovarian cancer drug - ETHealthWorld.com (NASDAQ:ABIO) health.economictimes.indiatimes.com - April 2 at 1:30 PM
	ARCA Biopharma, Inc. (ABIO) Analyst Review - Risers & Fallers (NASDAQ:ABIO) www.risersandfallers.com - April 2 at 1:30 PM
	Atrial fibrillation 2016 market pipeline review research made available by top research firm (NASDAQ:ABIO) www.whatech.com - April 2 at 1:30 PM
	NRPB & Pharma Innovation Partnerships 2015 -- Highlights - SYS-CON Media (press release) (NASDAQ:ABIO) news.sys-con.com - March 30 at 2:39 PM
	Vhcp Management Lowers stake in Arca Biopharma Inc (ABIO) - Los Angeles Mirror (NASDAQ:ABIO) www.losangelesmirror.net - March 30 at 2:39 PM
	In Focus Stocks: ARCA biopharma (NASDAQ:ABIO), Advanced Energy Industries (NASDAQ:AEIS), Shell Midstream ... - Property Mentor (NASDAQ:ABIO) www.propertymentorgroup.com - March 26 at 2:27 PM
	Analyst Coverage Updates - ARCA Biopharma, Inc. (ABIO) - Risers & Fallers (NASDAQ:ABIO) www.risersandfallers.com - March 26 at 2:27 PM
	ARCA BIOPHARMA, INC. Financials (NASDAQ:ABIO) finance.yahoo.com - March 23 at 1:04 PM
	After Last Week What Do Analysts Think Of ARCA Biopharma, Inc. (ABIO)? - Risers & Fallers (NASDAQ:ABIO) www.risersandfallers.com - March 20 at 2:51 PM
	TTHI, HBIO Put On Notice, Elite Gets FDA Date, VYGR Gets Ready To Sail - Nasdaq (NASDAQ:ABIO) www.nasdaq.com - March 19 at 12:56 PM
	ARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi (NASDAQ:ABIO) biz.yahoo.com - March 17 at 4:44 PM
	Bearish case for Valeant (NASDAQ:ABIO) finance.yahoo.com - March 17 at 2:25 PM
	GENETIC-AF Clinical Trial for Prevention of Atrial Fibrillation Enrolls 50th Patient (NASDAQ:ABIO) finance.yahoo.com - January 12 at 8:30 AM
	Applying Lessons from KBIO (NASDAQ:ABIO) finance.yahoo.com - December 8 at 9:00 AM
	2 Micro-Cap Opportunities in Atrial Fibrillation (NASDAQ:ABIO) finance.yahoo.com - November 30 at 9:38 AM